Patients with atopic dermatitis experienced improvements in severity with 16 weeks of tralokinumab despite the number of ...

Patients with AD treated with dupilumab have a lower risk of various infections than those treated with methotrexate or cyclosporine.

Direct immunofluorescence biopsy may be a useful tool in the diagnosis of pediatric patients with potential immune-mediated skin disorders.

Dupilumab in combination with other biologic agents is safe and effective for treating various chronic inflammatory conditions.